Table 1.
Relationship between clinical factors and serum exosomal miR-29b expression level
| Characteristic | Patients (N=107) | miR-29b high (n=48) | miR-29b low (n=59) | P |
|---|---|---|---|---|
| Sex | 0.2244 | |||
| Man | 56 | 22 | 34 | |
| Woman | 51 | 26 | 25 | |
| Age | 0.7488 | |||
| <50 | 45 | 21 | 24 | |
| ≥50 | 62 | 27 | 35 | |
| Tumor size (cm) | 0.1251 | |||
| <5 | 47 | 25 | 22 | |
| ≥5 | 60 | 23 | 37 | |
| MGMT status | 0.0189 | |||
| Unmethylated | 58 | 20 | 38 | |
| Methylated | 49 | 28 | 21 | |
| IDH1 status | 0.0341 | |||
| Mutated | 36 | 11 | 25 | |
| Wild-type | 71 | 37 | 34 | |
| Preoperative KPS | 0.0404 | |||
| <80 | 38 | 12 | 26 | |
| ≥80 | 69 | 36 | 33 |
MGMT, O-6-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; KPS, Karnofsky performance scale.